2020
Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches
Roque A, Omuro A. Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches. 2020, 217-226. DOI: 10.1007/978-3-030-59558-6_14.Peer-Reviewed Original ResearchLarge-scale genetic analysisEpigenetic informationMutation-specific approachesGenetic analysisMolecular characterizationMeningioma tumorigenesisMutational loadMethylation statusAbove mutationsMutationsMolecular landscapeMolecular changesNF2 geneGenesCurrent understandingAggressive phenotypeNF2 mutationsNew avenuesPotential biomarkersKLF4AKT1TumorigenesisPhenotypeTherapeutic interventionsTRAF7
2017
Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.
Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. Journal Of Clinical Oncology 2017, 35: 11549-11549. DOI: 10.1200/jco.2017.35.15_suppl.11549.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemTreatment responseCTC enumerationLM progressionCSF cytologyPhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentCycle 1IT trastuzumabEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningDisease progressionEarly biomarkersCerebrospinal fluidDay 1Colon cancerPotential biomarkersDiagnostic marker